Holen Sie sich die Stockscreener-App
14.09
1.47%
-0.21
Handel nachbörslich:
14.05
-0.04
-0.28%
Schlusskurs vom Vortag:
$14.30
Offen:
$14.23
24-Stunden-Volumen:
1.15M
Relative Volume:
1.81
Marktkapitalisierung:
$713.28M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-2.6787
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
-1.81%
1M Leistung:
+5.23%
6M Leistung:
+71.62%
1J Leistung:
+94.88%
1-Tages-Spanne:
$13.66
$14.44
1-Wochen-Bereich:
$13.66
$14.72
52-Wochen-Spanne:
$5.035
$15.41
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Vergleichen Sie RGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
14.09 | 723.91M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-07 | Fortgesetzt | Raymond James | Outperform |
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
REGENXBIO (NASDAQ:RGNX) Trading Down 3.8%Here's Why - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Behavioral Patterns of RGNX and Institutional Flows - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts By Investing.com - Investing.com Australia
Stifel Maintains REGENXBIO (RGNX) Buy Recommendation - Nasdaq
REGENXBIO (NASDAQ:RGNX) Shares Up 9.2%What's Next? - MarketBeat
What hedge fund activity signals for REGENXBIO Inc. stockCPI Data & Breakout Confirmation Trade Signals - DonanımHaber
Stifel Raises Price Target for Regenxbio (RGNX) to $45 | RGNX St - GuruFocus
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts - Investing.com Nigeria
Decliners Report: How interest rate cuts could boost REGENXBIO Inc. stockQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Why REGENXBIO Inc. stock is recommended by analystsTreasury Yields & Detailed Earnings Play Alerts - DonanımHaber
Squarepoint Ops LLC Boosts Holdings in REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. stock reach Wall Street targetsForecast Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is REGENXBIO Inc. stock a smart buy before Fed meetingJuly 2025 Trends & Scalable Portfolio Growth Ideas - ulpravda.ru
How interest rate cuts could boost REGENXBIO Inc. stockPortfolio Gains Report & Consistent Return Investment Signals - Улправда
Is REGENXBIO Inc. stock a contrarian buy2025 Risk Factors & Fast Entry Momentum Trade Alerts - Улправда
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - The AI Journal
Leerink Partners Maintains REGENXBIO (RGNX) Outperform Recommendation - Nasdaq
Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity By Investing.com - Investing.com South Africa
Regenxbio (RGNX): Leerink Partners Raises Price Target to USD 20 - GuruFocus
Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity - Investing.com Nigeria
REGENXBIO (NASDAQ:RGNX) Reaches New 1-Year HighWhat's Next? - MarketBeat
RegenXBio’s gene therapy study for Hunter syndrome: A potential game-changer - MSN
RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer - TipRanks
REGENXBIO (NASDAQ:RGNX) Stock Price Up 5.2%Time to Buy? - MarketBeat
(RGNX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
REGENXBIO (NASDAQ:RGNX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Wet Age-Related Macular Degeneration Market Growth - openPR.com
Voss Capital LP Boosts Stock Holdings in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. $RGNX is 22NW LP's 5th Largest Position - MarketBeat
Regenxbio Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser
What insider trading reveals about REGENXBIO Inc. stockJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
Why global investors buy REGENXBIO Inc. (RB0) stock2025 Market WrapUp & Safe Capital Allocation Plans - Newser
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulus2025 Big Picture & Safe Entry Zone Identification - Newser
Can REGENXBIO Inc. stock resist market sell offsQuarterly Profit Review & Technical Pattern Based Signals - Newser
Is REGENXBIO Inc. stock resilient to inflationGold Moves & Fast Exit Strategy with Risk Control - Newser
JPMorgan Chase & Co. Sells 512,318 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. (RB0) stock see valuation expansionWeekly Trade Analysis & Reliable Trade Execution Plans - Newser
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights
How (RGNX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
26,773 Shares in REGENXBIO Inc. $RGNX Bought by Rockefeller Capital Management L.P. - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):